Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN
Silexion Therapeutics Corp shares soared on Nasdaq Wednesday, ending the session up 96.95% at $0.5298. Shares had finished at $0.269 the day before. After the close, the stock dropped 9.5% in after-hours action. Volume topped 325 million shares as the low-priced cancer drug developer drew heavy trading.
